Dipeptidyl peptidase 4 promotes peritoneal fibrosis and its inhibitions prevent failure of peritoneal dialysis
Open Access
- 29 January 2021
- journal article
- research article
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-14
Abstract
Peritoneal dialysis (PD) possesses multiple advantages for end stage renal disease. However, long-term PD triggers peritoneal fibrosis (PF). From the nationwide analysis of diabetic PD patients (n = 19,828), we identified the incidence of PD failure was significantly lower in diabetic patients treated with dipeptidyl peptidase 4 (DPP4) inhibitors. Experimental study further showed high concentration of glucose remarkably enhanced DPP4 to promote epithelial-mesenchymal transition (EMT) in the mesothelial cells. In chlorhexidine gluconate (CG)-induced PF model of rats, DPP4 expression was enriched at thickening peritoneum. Moreover, as to CG-induced PF model, DPP4 deficiency (F344/DuCrlCrlj strain), sitagliptin and exendin-4 treatments significantly inhibited DPP4 to reverse the EMT process, angiogenesis, oxidative stress, and inflammation, resulting in the protection from PF, preservation of peritoneum and the corresponding functional integrity. Furthermore, DPP4 activity was significantly correlated with peritoneal dysfunction. Taken together, DPP4 caused peritoneal dysfunction/PF, whereas inhibition of DPP4 protected the PD patients against PD failure.Keywords
Funding Information
- Chang Gung Memorial Hospital (CMRPG8H1231)
This publication has 59 references indexed in Scilit:
- Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-β1 signalingKidney International, 2013
- Global Trends in Rates of Peritoneal DialysisJournal of the American Society of Nephrology, 2012
- Pathophysiological Changes to the Peritoneal Membrane during PD-Related Peritonitis: The Role of Mesothelial CellsMediators of Inflammation, 2012
- Possible involvement of SDF-1α/CXCR4-DPPIV axis in TGF-β1-induced enhancement of migratory potential in human peritoneal mesothelial cellsCell and tissue research, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Chronic Kidney Disease and Mortality RiskJournal of the American Society of Nephrology, 2006
- The biology of incretin hormonesCell Metabolism, 2006
- Peritoneal Inflammation and High Transport StatusClinical Journal of the American Society of Nephrology, 2006
- The mesothelial cellThe International Journal of Biochemistry & Cell Biology, 2004
- Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentrationKidney International, 2003